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(pain and function) translated into an improvement of SF12 physical
component. Improvement was achieved as from W6 and maintained up to
W24. Changes of the VAS and LFI score between baseline and W24 were
respectively -29,0 (21,9) and -4,1 (3,1) in Structum group and -29,9 (22,3)
and -4,1 (3,2) in Chondrosulf group. OMERACT-OARSI responders rates at
week 24 were 76,3% in Structum and 73,8% in Chondrosulf group (PP).
Rescue medication use (paracetamol and/or NSAIDs) was low and similar
in the 2 groups. 37.4% and 33.1% in the Structum and in the Chondrosulf
group respectively did not take any rescue medication. Both treatments
were well tolerated with a discontinuation rate for safety of 2.4% in the
Structum group and 4.5% in Chondrosulf group.
Conclusions: Structum® 1000mg (500mg BID) and Chondrosulf® 1200mg
(400mg TID) were equally effective on pain relief and functional improve-
ment in patients with symptomatic knee OA over a 6 month period of
time. The improvement started as early as week 6 and persists over the 24
weeks. Eﬃcacy was also conﬁrmed by the high rate of responders, around
75% in each group.
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F.P. Lafeber1
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Purpose: Selective COX-2 inhibitors are frequently used in treatment of
osteoarthritis (OA) to control inﬂammation and relieve pain. In vitro and
ex vivo research using human articular cartilage, demonstrated an inﬂam-
mation independent chondroprotective effect of celecoxib. Such effects are
diﬃcult to verify in clinical trials because changes in OA cartilage, degen-
erative and reparative, are slow and evaluation by image and biomarker
techniques are still hampered by their limited sensitivity. Therefore, pa-
tients were treated in vivo several weeks prior to joint replacement surgery.
At the moment of surgery, cartilage was obtained and analyzed ex vivo
in detail. Three recent small studies using this approach demonstrated a
beneﬁcial effect of celecoxib at chondrocyte mRNA and protein level, and
at the level of matrix integrity suggesting disease modifying characteristics
of celecoxib.
These positive results tempted us to perform a well designed and powered
RCT to evaluate the disease modifying properties of celecoxib in treatment
of end-stage OA.
Methods: Patients (n=172) with end-stage knee OA on the waiting list for
knee replacement surgery were randomized to 4 groups and treated for at
least 4 weeks prior to surgery: celecoxib 2dd200mg, naproxen 2dd250mg
stopped 3 days prior to surgery (because of its platelet-inhibiting effect),
celecoxib 2dd200mg also stopped 3 days prior to surgery, or no treatment.
Cartilage and synovial tissue were collected during surgery and analyzed
in detail ex vivo fully blinded to the treatment until all data were ob-
tained. Primary outcome was cartilage proteoglycan release. Additionally,
several biochemical markers of cartilage integrity and synovial inﬂamma-
Abstract 329 – Table 1. Changes in Proprioception scores
Variable Mean Scores (SD) Change from BaselineMean (SD) Total Number of Subjects P-value Tai Chi vs. Control
Tai Chi (N=20) Control (N=20) Tai Chi Control
30 Degrees
Baseline 5.58 (4.15) 4.26 (2.88)
Week 12 3.00 (2.55) 6.55 (4.38) -2.53 (5.22) 2.11 (5.64) 40 0.01
Week 24 3.60 (4.58) 3.80 (2.50) -2.58 (5.84) -0.68 (2.60) 40 0.20
Week 48 4.10 (2.79) 4.79 (4.70) -1.26 (4.75) -0.11 (4.42) 39 0.40
45 Degrees
Baseline 4.60 (4.03) 3.63 (3.08)
Week 12 4.00 (3.29) 4.75 (4.12) -0.60 (5.06) 0.95 (5.04) 40 0.30
Week 24 2.75 (2.59) 1.65 (1.73) -1.85 (4.40) -1.95 (3.27) 40 0.90
Week 48 2.75 (1.55) 3.00 (2.98) -1.85 (4.52) -1.22 (4.41) 39 0.70
60 Degrees
Baseline 3.05 (3.05) 3.24 (2.93)
Week 12 2.45 (2.44) 2.84 (2.61) -0.60 (4.03) 0.06 (3.80) 39 0.60
Week 24 1.94 (2.46) 3.60 (3.31) -1.18 (3.28) -0.88 (3.76) 27 0.80
Week 48 3.21 (2.44) 1.94 (1.89) 0.26 (4.59) -1.44 (4.11) 37 0.30
tion were determined. The WOMAC questionnaire was used to evaluate
pain, stiffness and function before and after treatment. The study was
conducted according to the declaration of Helsinki and registered EudraCT
nr 2007-004862-41.
Results: 4 patients withdrew their consent, 10 changed medications within
2 weeks, and of 20 patients insuﬃcient tissue was obtained. Drop-outs
were equally distributed over the 4 treatment arms. Data were analyzed
by intention to treat as well as per protocol of the remaining 138 pa-
tients. At inclusion, age, gender, weight (BMI) and cartilage damage (X-ray,
macroscopic or histological) did not differ between the 4 randomized
groups. Unexpectedly, cartilage proteoglycan release was not different
between the 4 treatments. Also the other biochemical cartilage parameters
did not differ between the 4 groups. Furthermore, prostaglandin-E2 and
nitric oxide (NO) levels produced by the cartilage remained unchanged
compared to the no-treatment group. The ex vivo release of inﬂammatory
mediators IL-1β, TNFα, PGE2 and NO by the synovial tissue only showed a
statistical signiﬁcant decrease in NO levels in the celecoxib treated group
compared to the no-treatment group. Celecoxib treatment showed a slight
improvement in WOMAC pain (p<0.01), function and total score compared
to the no-treatment group.
Conclusions: No clear effect of celecoxib treatment on cartilage was evident
in the present study. Also the effects on synovial inﬂammatory mediators
were limited. Only a small beneﬁcial effect on WOMAC scores was found.
As such the reported in vivo disease modifying effects of celecoxib could
not be conﬁrmed in a suﬃciently powered single blinded RCT.
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CONTROLLED TRIAL
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Tufts Med. Ctr., Boston, MA
Purpose: Neurologic deﬁcits, especially quadriceps sensory dysfunction
(i.e., decreased proprioceptive acuity) may precede Knee Osteoarthritis
(KOA) and are proposed to be a factor in its pathogenesis or progression.
Tai Chi may provide ideal proprioceptive exercise to older individuals
with KOA through its emphasis on balance, muscle strengthening, and
integration of the mind and body. Previous long-term observational stud-
ies found that Tai Chi practitioners had better knee-joint proprioceptive
acuity versus controls in an older population. We evaluated the effects of
Tai Chi for knee-joint proprioception in KOA in a randomized controlled
trial.
Methods: We randomized 40 eligible individuals (age > 55, BMI ≤ 40
kg/m2 with knee pain on most days of the previous month and tibiofemoral
OA K/L grade ≥2) to Tai Chi (10 modiﬁed forms from classical Yang style)
or an attention control (stretching and wellness education). The 60-minute
intervention sessions occurred twice-weekly for 12 weeks. The knee joint
proprioception was measured using a Biometrics™ electrogoniometer with
an ADU301 angle display unit during each assessment visit. Three test
angles (30, 45 and 60 degrees) were evaluated with each subject in a
sitting position taken as neutral (0 degree). The electrogoniometer was
placed longitudinally in alignment with the femur and tibia with double-
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sided medical tape and used to determine each of the three test angles.
Participants were ﬁrst shown one of the angles, which was held for a few
seconds, then were asked to close their eyes and attempt to reproduce the
angle; this was repeated for all three test angles. We also repeated these
assessments at 24 and 48 weeks to test durability of response. The mean
error (absolute angle error) between the actual and replicated angles was
calculated for each of the three test angles. The Tai Chi and control groups
were compared by intention-to-treat using t-tests.
Results: The participants had a mean age of 65y (SD 7.8), mean disease
duration 10y (SD 7.6), mean BMI 30.0 kg/m2 (SD 4.8), and median K/L
grade 4; 75% were female, 70% were white. There were no signiﬁcant
differences at baseline in demographics, radiographic score, and outcome
measures. Attendance rate was 85% in the Tai Chi versus 89% in the
attention control. Participants in the Tai Chi arm exhibited signiﬁcantly
improved proprioception at 30 degrees, but not at 45 and 60 degrees, at
12 weeks (Table 1). Patients who continued Tai Chi practice after 12 weeks
also reported no signiﬁcant improvements in knee proprioception at 24
and 48 weeks.
Conclusion: We were not able to demonstrate in this pilot study that
Tai Chi is beneﬁcial for knee proprioception in people with severe KOA.
Potential confounders of the test including baseline characteristics, knee
pain severity, effusion and function, modiﬁed Tai Chi style, changes in joint
position and body weight, small sample size may limit data interpretation
and evaluation of the results. Standardized and reproducible measures for
knee proprioception should be explored in the future research.
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1Univ. of Maryland Sch. of Med., Baltimore, MD; 2Northwestern Univ., Chicago,
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Purpose: In previous studies, naproxcinod, a novel cyclooxygenase inhibit-
ing nitric oxide donator (CINOD), has shown eﬃcacy similar to naproxen
in the treatment of the signs and symptoms of hip and knee osteoarthritis
(OA), but with effects on blood pressure (BP) similar to placebo. The
objective of this analysis is to determine if nitric oxide donation from
naproxcinod contributes to any difference in change in joint space width in
the tibio-femoral joint over one year compared to naproxen.
Methods: Data were analyzed from a 53-week, randomized, double-blind,
parallel-group clinical trial of 1020 patients with idiopathic knee OA who
were randomized to naproxcinod 750 mg, naproxcinod 375 mg, naproxen
500 mg or placebo (all bid) for 13 weeks; patients who had received
placebo were then re-randomized to naproxcinod either 750 mg or 375 mg
bid. Weight-bearing posterior-anterior (PA) radiographs were obtained in
the semiﬂexed position with a standard protocol by radiology technicians
using the SynaFlexer™ positioning device at baseline (between 4 and
10 days prior to randomization) and after 52 weeks in patients who
completed the study. All images (either hard copy or digital) were sent to
Synarc Inc. (San Francisco, CA) for quality assessment. A single trained and
certiﬁed radiologist measured minimum joint space width (JSW) using a
semiautomatic computer program on digitized images that were paired by
subject but randomized and blinded to time sequence. Mean (SD) change
in minimum JSW by compartment in the index knee was calculated for
each treatment group. No statistical comparisons were performed of this
exploratory safety endpoint.
Results: A total of 1020 patients with idiopathic knee OA were enrolled in
the study and randomized to one of the four treatment groups: mean (SD)
Table 1
All in Millimeters Naproxcinod 750 Naproxcinod 375 Naproxen 500
Medial compartment
Mean change (SD) 0.130 (0.92) -0.064 (0.812) 0.118 (1.18)
Median change (min, max) 0.00 (-2.06, 3.79) -0.01 (-4.22, 1.98) 0.00 (-3.73, 6.87)
Lateral compartment
Mean change (SD) -0.109 (1.23) -0.145 (0.98) -0.153 (1.22)
Median change (min, max) -0.06 (-5.58, 3.50) -0.02 (-3.66, 2.00) -0.08 (-6.15, 3.24)
age 59.8 (9.8) years, 709 (71%) women, 789 (79%) white, mean BMI 33.8
kg/m2. A total of 391 subjects completed 52 weeks on study medication
and had paired knee x-rays that were read for minimum JSW at both time
points. Mean and median changes in minimum JSW in both the medial and
lateral compartments are shown in Table 1.
Conclusions: These data show no signiﬁcant difference in JSW change for
naproxcinod as compared to naproxen over one year. Changes in minimum
JSW seen in this study were consistent with data reported in published
literature for patients with knee OA.
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DISABILITY AMONG PEOPLE WITH SYMPTOMATIC KNEE OSTEOARTHRITIS
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1Univ. of Sydney, Lidcombe, Australia; 2The George Inst. for Intl. Hlth., Sydney,
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Purpose: To determine the association between knee pain and physical
function (last 48 hours) and health related quality of life (past 4 weeks) and
prospective reporting of knee pain and global assessment of knee OA over
the following seven day period in a cohort of people with symptomatic
knee osteoarthritis participating in the two year Long-term Evaluation of
Glucosamine Sulphate (LEGS) study.
Methods: The LEGS study is a 2×2 factorial design randomised placebo-
controlled clinical trial allocating participants to glucosamine sulphate
(1500mg) and chondroitin sulphate (800mg) or matching placebo for two
years. Participants are required to attend annual clinic assessments (includ-
ing WOMAC and SF-12 questionnaires) and complete a 7-day Participant
Diary collecting daily prospective data on knee pain (At its worst, how
much pain did you have in your knee today? 0-10 (No pain to worst
pain) and a global assessment (Considering all the ways your knee arthritis
affects you, how would you say your knees are today? Excellent to Poor).
For each participant both the average knee pain score and the highest score
reported over 7 days was extrapolated for analysis. For each scale, apart
from the SF-12, higher scores indicate more pain or disability.
Results: A total of 605 people with mild to moderate symptomatic knee
OA were randomised (October 2007-2009) and completed the baseline
clinic assessment and the immediately following 7-day Participant Diary
reporting (Table 1).
Table 1. Baseline pain and disability
Clinic Assessment Mean (sd)
Age 60.3 (8.2)
Female (n,%) 339, 56%
BMI 28.9 (5.8)
Obese (n, %) 214, 35%
WOMAC pain (0-100) 33.2 (17.6)
WOMAC function (0-100) 32.4 (18.2)
SF-12 PCS 41.3 (9.5)
SF-12 MCS 52.8 (10.0)
7-day Participant Diary Mean (sd)
Left knee pain (0-100) 34.1 (18.6)
Right knee pain 33.4 (19.3)
Left highest knee pain 47.2 (20.9)
Right highest knee pain 44.9 (21.1)
• Excellent 23 (4%)
• Very good 93 (16%)
• Good 210 (36%)
• Fair 234 (41%)
• Poor 17 (3%)
The correlation between WOMAC pain and physical function scores was
unexpectedly strong (r=0.80). Unsurprisingly, there was no correlation
between the SF-12 PCS and the SF-12 MCS score (r=-0.10).
There were meaningful correlations between the WOMAC scores (past 48
hours) and prospective Participant Diary daily pain (r=0.47 to 0.54) and
global assessment of arthritis scores (r=0.45 to 0.46). There were smaller
corrections between the SF-12 PCS and the Participant Diary daily pain
scores (r=-0.31 to -0.34) and little association between the SF-12 MCS and
the Participant Diary daily pain scores (r=-0.06 to -0.11).
